N. Ogama

Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels

T. Ebina, N. Ogama, H. Shimanuki, 2003, Cancer Immunology, Immunotherapy.

Effector Mechanism and Clinical Response of BAK (BRM‐Activated Killer) Immuno‐Cell Therapy for Maintaining Satisfactory QOL of Advanced Cancer Patients Utilizing CD56‐Positive NIE (Neuro‐Immune‐Endocrine) Cells

T. Ebina, N. Ogama, H. Shimanuki, 2001, Microbiology and immunology.

CD271 regulates the proliferation and motility of hypopharyngeal cancer cells

N. Tanaka, K. Sugamura, K. Yamaguchi, 2016, Scientific Reports.

Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.

N. Tanaka, K. Yamaguchi, K. Satoh, 2014, Biochemical and biophysical research communications.

Antitumor effects of pronase-treated fragments, glycopeptides, from ovomucin in hen egg white in a double grafted tumor system

Kenji Watanabe, M. Shimoyamada, T. Ebina, 1998 .

MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance

N. Tanaka, M. Kobayashi, K. Murayama, 2021, Cancer science.